[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients
Dik J. Kwekkeboom(Erasmus MC), Eric P. Krenning(Erasmus MC), Marion de Jong(Rotterdam University of Applied Sciences), Mark Konijnenberg(Mallinckrodt (Ireland)), Willem H. Bakker(Erasmus MC), P.P.M. Kooij(Erasmus MC), Ananth Srinivasan(Mallinckrodt (United States)), Jack L. Erion(Moffitt Cancer Center), Joe L. Bugaj(Mallinckrodt (United States)), Michelle Schmidt(Mallinckrodt (United States))
Cited by 471
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
|Neuroendocrinology|2012|869
The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors
|Endocrine Reviews|1991|814